Supernus Pharmaceuticals | SUPN - Current Assets


Supernus Pharmaceuticals reported $731.58M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Abbott USD 25.51B 488M Mar/2026
ANI Pharmaceuticals USD 747.08M 6.03M Mar/2026
Aurora Cannabis CAD 445.84M 22M Dec/2025
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Canopy Growth CAD 524.67M 78.85M Dec/2025
Cara Therapeutics USD 31.54M 6.9M Dec/2025
Corcept Therapeutics USD 426.03M 59.43M Mar/2026
Eisai JPY 761.64B 79.24B Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
Novo Nordisk DKK 177.32B 4.86B Mar/2026
Pacira USD 514.96M 33.01M Mar/2026
Perrigo USD 2.71B 85M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Supernus Pharmaceuticals USD 731.58M 87.4M Mar/2026
United Therapeutics USD 2.87B 830.5M Mar/2026
Xeris Pharmaceuticals USD 251.68M 11.37M Mar/2026